Steward Partners Investment Advisory LLC Buys New Shares in CEL-SCI Co. (NYSEAMERICAN:CVM)

Share on StockTwits

Steward Partners Investment Advisory LLC bought a new stake in CEL-SCI Co. (NYSEAMERICAN:CVM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,009 shares of the company’s stock, valued at approximately $25,000.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of CEL-SCI by 5.0% during the fourth quarter. BlackRock Inc. now owns 634,031 shares of the company’s stock valued at $1,820,000 after purchasing an additional 30,117 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of CEL-SCI during the fourth quarter valued at about $38,000. Commonwealth Equity Services LLC raised its holdings in shares of CEL-SCI by 36.2% during the second quarter. Commonwealth Equity Services LLC now owns 139,564 shares of the company’s stock valued at $1,169,000 after purchasing an additional 37,109 shares during the period. Thoroughbred Financial Services LLC raised its holdings in shares of CEL-SCI by 21.1% during the first quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock valued at $49,000 after purchasing an additional 2,428 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of CEL-SCI during the first quarter valued at about $42,000.

NYSEAMERICAN:CVM opened at $7.86 on Friday. CEL-SCI Co. has a one year low of $1.38 and a one year high of $8.99.

CEL-SCI (NYSEAMERICAN:CVM) last posted its earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.27). The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Read More: Why is the ex-dividend date different from the record date?

Want to see what other hedge funds are holding CVM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CEL-SCI Co. (NYSEAMERICAN:CVM).

Institutional Ownership by Quarter for CEL-SCI (NYSEAMERICAN:CVM)

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Steward Partners Investment Advisory LLC Buys New Stake in Alcoa Corp
Steward Partners Investment Advisory LLC Buys New Stake in Alcoa Corp
Steward Partners Investment Advisory LLC Purchases Shares of 612 BorgWarner Inc.
Steward Partners Investment Advisory LLC Purchases Shares of 612 BorgWarner Inc.
Steward Partners Investment Advisory LLC Purchases New Shares in Chemical Financial Co.
Steward Partners Investment Advisory LLC Purchases New Shares in Chemical Financial Co.
Steward Partners Investment Advisory LLC Invests $25,000 in Chatham Lodging Trust
Steward Partners Investment Advisory LLC Invests $25,000 in Chatham Lodging Trust
Steward Partners Investment Advisory LLC Buys New Shares in CEL-SCI Co.
Steward Partners Investment Advisory LLC Buys New Shares in CEL-SCI Co.
Steward Partners Investment Advisory LLC Makes New Investment in 1st Tr EXCHANGE/ENERGY ALPHADEX FDA
Steward Partners Investment Advisory LLC Makes New Investment in 1st Tr EXCHANGE/ENERGY ALPHADEX FDA


© 2006-2019 Ticker Report